Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient willing and able to provide written willing to sign a consent form to participate in the study - Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis - Aged ≥18 years at the time of signing the willing to sign a consent form - Patient willing and able to participate in collection of electronic patient reported outcomes (PROs) Who Should NOT Join This Trial: - Concurrent participation in any interventional trial for ATTR amyloidosis - Involvement in the planning and/or conduct of the current study - Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA) - Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patient willing and able to provide written informed consent to participate in the study * Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis * Aged ≥18 years at the time of signing the informed consent * Patient willing and able to participate in collection of electronic patient reported outcomes (PROs) Exclusion Criteria: * Concurrent participation in any interventional trial for ATTR amyloidosis * Involvement in the planning and/or conduct of the current study * Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA) * Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Treatments Being Tested

DRUG

Treatment of transthyretin (ATTR) amyloidosis in observational study setting

Data will be collected on patients with ATTR amyloidosis in a real-world setting

Locations (20)

Research Site
La Jolla, California, United States
Research Site
Los Angeles, California, United States
Research Site
San Francisco, California, United States
Research Site
San Francisco, California, United States
Research Site
New Haven, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Chicago, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
Rochester, Minnesota, United States
Research Site
Kansas City, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
New Brunswick, New Jersey, United States
Research Site
Manhasset, New York, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Danville, Pennsylvania, United States